Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or PALB2 PVs Have Similar Mortality to the Average Genetically Tested Patients By Ogkologos - March 18, 2025 713 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a population-based study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR EMA Recommends Extending Indications for Pembrolizumab to Include Adjuvant Treatment in... October 6, 2023 FDA Approves Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma February 15, 2024 Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer May 28, 2020 How does processed and red meat cause cancer and how much... March 17, 2021 Load more HOT NEWS The HPV Vaccine: Increasing the Use of an Important Cancer Prevention... Promising Results Demostrated with Novel Subcutaneously Adminstered Envafolimab in Patients with... A Combination of Amivantamab and Lazertinib Shows Durable Clinical Activity in... ESMO Issues First Recommendations on Using Next-Generation Sequencing for Advanced Cancers...
